A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer

Phase 1

Recruiting

• Conditions: Breast Cancer
• Interventions: Drug: HS-10352 combined with fulvestrant (Stage 1); Drug: HS-10352 combined with fulvestrant (Stage 2)

• Registration Number: NCT05504213
• Lead Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Brief Summary

HS-10352 is a highly potent and selective small molecule inhibitor of phosphoinositide 3-kinase (p110α). The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10352 plus fulvestrant in patients with hormone receptor (HR) positive, human epidermal growth factor 2 (HER2)-negative, advanced breast cancer (ABC) harboring PIK3CA mutations.

Detailed Description

This is a Phase Ib open-label, 2-Part, multi-center study in China. The study will be conducted in two stages: Stage 1 is the dose-escalation part, which is designed to evaluate the safety, tolerability, PK and efficacy, as well as to determine the maximum tolerable dosage (MTD) or maximum applicable dose (MAD) of HS-10352 in combination with fulvestrant. Stage 2 is the dose-expansion part, which is aimed to further assess the efficacy, safety, tolerability and PK, and to establish the recommended phase 2 dose (RP2D) of HS-10352 in combination with fulvestrant.

All participants will be carefully monitored for adverse events (AE) during the study treatment and for 28 days after the last dose of study drug. The PK characteristics of HS-10352 and fulvestrant will be evaluated from C1 to C6. Subjects of this study will be assessed for progression once every 8 weeks until objective disease progression or withdrawal from the trial. As the disease progresses, survival follow-up is recommended bimonthly.

Study Timeline

• Study Start: 2022-01-12
• Status Verified: 2022-05
• Study First Submitted: 2022-05-17
• Study First Submitted QC: 2022-08-15
• Last Update Submitted: 2022-08-15
• Study First Posted: 2022-08-17
• Last Update Posted: 2022-08-17
• Primary Completion: 2023-07-31
• Study Completion: 2025-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 224

Inclusion Criteria

1. Men or women aged more than or equal to (≥) 18 years

2. HR+ HER2- breast cancer confirmed by histology or cytology.

3. Locally advanced disease not amenable to curative treatment by surgery or metastatic disease.

4. Have adequate tumor tissue for the analysis of PIK3CA mutational status. At dose expansion stage, participants should be identified as PIK3CA-mutation positive before enrollment.

5. Females should have postmenopausal status due to either surgical/natural menopause or ovarian suppression with a luteinizing hormone releasing hormone (LHRH) agonist before enrollment. Males should be pre-treated with a LHRH agonist.

6. Have either measurable disease per RECIST v1.1 criteria or at least one predominantly lytic bone lesion must be present.

7. ECOG performance status was 0-1 and did not deteriorate in the previous 2 weeks.

8. Estimated life expectancy for at least three months

9. Females should be using adequate contraceptive measures and should not be breastfeeding at the time of screening, during the study and until 6 months after completion of the study; and have negative results of blood pregnancy test prior to C1D1.

   Males should be using adequate contraceptive measures at the time of screening, during the study and until 6 months after completion of the study.

10. Have signed Informed Consent Form

11. Dose escalation stage-Cohort 1: subjects resistant to endocrine therapy Dose expansion stage-Cohort 2: subjects resistant to endocrine therapy Dose expansion stage-Cohort 3: endocrine therapy-sensitive or endocrine-naive subjects

Exclusion Criteria

1. Participant with symptomatic visceral disease or any disease burden that makes the participant ineligible for endocrine therapy per the investigator's best judgment

2. Treatment with any of the following:

   1. Previous or current treatment with PI3K, AKT or mTOR inhibitors
   2. For expansion stage, prior treatment with fulvestrant
   3. Any cytotoxic chemotherapy, investigational agents within 21 days of the first dose of study drug; anticancer drugs which have been received within 14 days before the first administration.
   4. Radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study drug, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks of the first dose.
   5. Major surgery (including craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks of the first dose of study drug.

3. With inflammatory breast cancer at screening.

4. Inadequate bone marrow reserve or organ function.

5. Uncontrolled pleural effusion or ascites or pericardial effusion.

6. Known and untreated, or active central nervous system metastases.

7. History of primary or secondary diabetes.

8. History of acute or chronic pancreatitis

9. Refractory nausea, vomiting, or chronic gastrointestinal diseases, or inability to swallow the study drug that would preclude adequate absorption of HS-10352 or fulvestrant.

10. History of hypersensitivity to any active or inactive ingredient of HS-10352/ fulvestrant or to drugs with a similar chemical structure or class to HS-10352.

11. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.

12. Any disease or condition that, in the opinion of the investigator, would compromise the safety of the patient or interfere with study assessments.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Cohort 1: Endocrine therapy-resistant (Stage 1)	HS-10352 combined with fulvestrant (Stage 1)	Participants who are endocrine therapy pre-treated will be administrated at escalating doses orally of HS-10352 in combination with fulvestrant (500 mg, intramuscular).
Cohort 2: Endocrine therapy-resistant (Stage 2)	HS-10352 combined with fulvestrant (Stage 2)	Participants who are endocrine therapy-resistant will be treated with HS-10352 orally at the MTD/MAD identified in Stage 1 or/and lower dose in combination with fulvestrant (500 mg, intramuscular)
Cohort 3: Endocrine therapy-sensitive or endocrine-naïve (Stage 2)	HS-10352 combined with fulvestrant (Stage 2)	Participants who are endocrine therapy-sensitive or naïve will be treated with HS-10352 orally at MTD/MAD or/and lower dose identified in Stage 1 in combination with fulvestrant (500 mg, intramuscular)

Primary Outcome Measures

Name	Time	Method
[Stage 1] Maximum tolerated dose (MTD) of HS-10352 in combination with fulvestrant	Cycle 1 (28 days)	MTD is defined as the previous dose level at which 2 or more out of 2\~6 subjects experienced a DLT.
[Stage 2] Objective response rate (ORR) of HS-10352 in combination with fulvestrant	From the date of first dose until the date of disease progression or withdrawal from study, approximately 3 years	ORR is defined as the proportion of participants with best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on assessment per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
[Stage 1] Maximum applicable dose (MAD) of HS-10352 in combination with fulvestrant	Cycle 1 (28 days)	MAD is defined as follows: a) based on PK data, it is anticipated that at this dose level, the dose-exposure plateau has been reached, b) based on existing safety data, it is judged that dose escalation following this dose level will have a large safety risk or subject intolerance, or c) based on the PK-PD model, it suggested that the optimal target concentration of safety and efficacy has been explored.

Secondary Outcome Measures

Name	Time	Method
[Stage 1 and Stage 2] PK parameters: time of the maximum concentration (Tmax) of HS-10352	Cycle 1 Day 1 (C1D1)，at the first day of Cycle 1 (each cycle is 28 days)	Defined as the time to reach maximum plasma concentration following drug administration of HS-10352
[Stage 1 and Stage 2] PK parameters: elimination half life (t1/2) of HS-10352	Cycle 1 Day 1 (C1D1)，at the first day of Cycle 1 (each cycle is 28 days)	Defines as the time measured for the concentration to decrease by one half.
[Stage 1 and Stage 2] PK parameters: area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration (AUC0-t) of HS-10352	Cycle 1 Day 1 (C1D1)，at the first day of Cycle 1 (each cycle is 28 days)	Defines as area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLOQ).
[Stage 1 and Stage 2] PK parameters: the minimum concentration at steady-state (Css,min) of fulvestrant	Cycle 2 (28 days)	Defines as the minimum plasma drug concentration of fulvestrant at steady-state
[Stage 1] Efficacy of HS-10352 in combination with fulvestrant: ORR	From the date of first dose until the date of disease progression or withdrawal from study, approximately 3 years	ORR is defined as the proportion of participants with BOR of confirmed CR or confirmed PR based on assessment per RECIST v1.1.
[Stage 1 and Stage 2] PK parameters: the maximum concentration at steady-state (Css,max) of HS-10352	Cycle 2 Day 1 (C2D1)，at the first day of Cycle 2 (each cycle is 28 days) each cycle is 28 days	Defines as the maximum plasma drug concentration of HS-10352 at steady-state
[Stage 1 and Stage 2] PK parameters: the minimum concentration at steady-state (Css,min) of HS-10352	Cycle 2 Day 1 (C2D1)，at the first day of Cycle 1 (each cycle is 28 days)	Defines as the minimum plasma drug concentration of HS-10352 at steady-state
[Stage 1] PK parameters: time of the maximum concentration (Tmax) of fulvestrant	Cycle 1 (28 days)	Defined as the time to reach maximum plasma concentration following drug administration of fulvestrant
[Stage 1 and Stage 2] PK parameters: area under the concentration-time curve over 24 hours (AUC0-24) of HS-10352	Cycle 1 Day 1 (C1D1)，at the first day of Cycle 1 (each cycle is 28 days)	Defines as area under the plasma concentration versus time curve from time zero to the 24-hour sampling time.
[Stage 1 and Stage 2] Incidence and severity of treatment-emergent adverse events	From Cycle 1 Day 1 (C1D1) until 28 days after the final dose. A cycle is 28 days.	Assessed by number and severity of adverse events as evaluated according to NCI CTCAE v5.0.
[Stage 1] PK parameters: the maximum concentration (Cmax) of fulvestrant	Cycle 1 (28 days)	Defines as the maximum plasma drug concentration of fulvestrant
[Stage 1] PK parameters: the maximum concentration at steady-state (Css,max) of fulvestrant	Cycle 2 (28 days)	Defines as the maximum plasma drug concentration of fulvestrant at steady-state
[Stage 1 and Stage 2] PK parameters: time of the maximum concentration at steady state (Tss,max) of HS-10352	Cycle 2 Day 1 (C2D1)，at the first day of Cycle 1 (each cycle is 28 days)	Defined as the time to reach maximum plasma concentration following drug administration of HS-10352 at steady-state
[Stage 1] PK parameters: time of the maximum concentration at steady state (Tss,max) of fulvestrant	Cycle 2 (28 days)	Defined as the time to reach maximum plasma concentration following drug administration of fulvestrant at steady-state
[Stage 1 and Stage 2] PK parameters: the maximum concentration (Cmax) of HS-10352	Cycle 1 Day 1 (C1D1)，at the first day of Cycle 1 (each cycle is 28 days)	Defines as the maximum plasma drug concentration of HS-10352
[Stage 1] PK parameters: area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration (AUC0-t) of fulvestrant	From Cycle 1 to Cycle 2， each cycle is 28 days	Defines as area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLOQ).
[Stage 1 and Stage 2] Efficacy of HS-10352 in combination with fulvestrant: disease control rate (DCR)	From the date of first dose until the date of disease progression or withdrawal from study, approximately 3 years	The disease control was defined as the percentage of patients who have a best overall response (confirmed CR, PR, or stable disease for at least 6 weeks).
[Stage 1 and Stage 2] Efficacy of HS-10352 in combination with fulvestrant: duration of response (DoR)	From the date of CR, PR until the date of disease progression or withdrawal from study, approximately 3 years	DOR only applies to participants whose best overall response is CR or PR based on assessment per RECIST v1.1. The start date is the date of first documented response of CR or PR (i.e. the start date of observed response, not the date when response was confirmed), and the end date is defined as the date of the first documented progression or death due to underlying cancer.
[Stage 1 and Stage 2] Efficacy of HS-10352 in combination with fulvestrant: progression free survival (PFS)	From the date of randomization or first dose (if randomization is not needed) until the date of disease progression or withdrawal from study, approximately 3 years	PFS is defined as the time from the date of randomization or first dose (if randomization is not needed) to the date of the first documented progression or death due to any cause. PFS will be assessed per RECIST v1.1.
[Stage 2] Efficacy of HS-10352 in combination with fulvestrant: overall survival (OS)	From the date of randomization or first dose (if randomization is not needed) until the documentation of death from any cause, approximately 6 years	OS is defined as the time from the date of randomization or first dose (if randomization is not needed) to the date of death due to any cause. For each participant who is not known to have died as of the cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.

Trial Locations

Locations (1)

Fudan University Shanghai Cancer Center; 🇨🇳 Shanghai, Shanghai, China